ITNS - Itonis, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD

Itonis, Inc.

22951 Mill Creek Drive
Suite A-1
Laguna Hills, CA 92653
United States

IndustryMedical Distribution
Full Time Employees3

Key Executives

NameTitlePayExercisedYear Born
Mr. Mark H. CheungCEO, Pres & DirectorN/AN/AN/A
Dr. Donald L. JollyCFO & TreasurerN/AN/AN/A
Mr. Corey WashingtonChief Technology OfficerN/AN/AN/A
Mr. Stephen R. Pidliskey Jr.VP & Sec.N/AN/AN/A
Dr. Charles B. Hensley Ph.D.Pres of Itonis PharmaceuticalsN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Itonis, Inc., a development stage company, focuses on producing and marketing over the counter and prescription homeopathic preparations to treat common ailments and chronic diseases. The company intends to sells its over-the-counter to alleviate mild to moderate nausea. It has placed a manufacturing order for the first batch of its Emesyl product line. The company was formerly known as Kenshou, Inc. and changed its name to Itonis, Inc. in December 2005. Itonis, Inc. was founded in 2005 and is headquartered in Laguna Hills, California.

Corporate Governance

Itonis, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.